Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

News

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

New York 2/23/2021 10:55:00 AM

AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the underwriter of its previously announced bought deal offering of common stock has partially exercised its option to purchase an additional 7,030,927 shares of common stock at a price to the public of $1.60 per share. After giving effect to the exercise of option to purchase additional shares, the total number of shares sold by AIkido in the bought deal offering increased to 53,905,927 shares and gross proceeds increased to approximately $86.2 million, before deducting underwriting discounts and commissions and other offering expenses.

(PRNewsfoto/AIkido Pharma Incorporated)
(PRNewsfoto/AIkido Pharma Incorporated)

H.C. Wainwright & Co. acted as the sole book-running manager for the offering.

The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.

 

The shares of common stock described above were offered pursuant to the registration statement on Form S-3 (File No. 333-238172), as amended, previously filed with and subsequently declared effective by the Securities and Exchange Commission ("SEC") on June 18, 2020. A final prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus relating to this offering may be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, New York 10022, by email at placements@hcwco.com or by telephone at 646-975-6996.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About AIkido Pharma Inc.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the SEC, not limited to Risk Factors relating to its business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact:

Investor Relations:

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido Pharma Inc.:
Phone: 212-745-1373
Email: investorrelations@aikidopharma.com
www.aikidopharma.com

More News

https://s3.amazonaws.com/findit-pictures/351133/5a9367a7-1d67-477a-8321-e8a4173d690f.jpg

Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin

Aikido Pharma Has Licensed DHA-dFdC at The University of Texas at Austin

Released On: 3/5/2021
Views: 930

https://s3.amazonaws.com/findit-pictures/351133/b9cc6d12-45b2-42d8-98c3-1ea2961eecad.jpg

Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC

Aikido Pharma Shares Published Papers and Articles on KPC-34 and DHA-dFdC

Released On: 3/3/2021
Views: 910

https://s3.amazonaws.com/findit-pictures/351133/86c80767-4bb8-48ba-b5be-f5c6e1ff2d4d.jpg

Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

Aikido Pharma Announces Findings of Positive Results From New Drug “DHA-dFdC” Developed at The University of Texas at Austin

Released On: 3/1/2021
Views: 940

https://s3.amazonaws.com/findit-pictures/351133/d1155add-3bd8-4751-8661-f9c48c2f069d.jpg

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

AIkido Pharma Inc. to Present at the H.C. Wainwright Global Life Sciences Conference (Virtual Event)

Released On: 3/1/2021
Views: 1350

https://s3.amazonaws.com/findit-pictures/351133/48a25696-dac4-4e6d-bc52-6d181debb131.jpg

Meet Aikido Pharma Inc’s Board of Directors

Meet Aikido Pharma Inc’s Board of Directors

Released On: 2/28/2021
Views: 958

https://s3.amazonaws.com/findit-pictures/351133/06f2c09a-2436-4e6b-8eb3-f07578c8ab17.jpg

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

AIkido Pharma Inc. Announces Exercise of Option to Purchase Additional Shares in Bought Deal Offering

Released On: 2/23/2021
Views: 979

https://s3.amazonaws.com/findit-pictures/351133/bf0df713-8e2e-44ac-9609-f12bdf9847eb.jpg

Artificial Intelligence Is Optimizing Drug Development

Artificial Intelligence Is Optimizing Drug Development

Released On: 2/22/2021
Views: 1004

https://s3.amazonaws.com/findit-pictures/351133/fad82173-54eb-4dcf-b365-5cf437598e16.jpg

Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer

Aikido Pharma Focuses on The Treatment of Four Main Types of Cancer

Released On: 2/20/2021
Views: 886

https://s3.amazonaws.com/findit-pictures/351133/f5052f01-a9c3-48cf-8558-12b7f8dd5d85.jpg

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

AIkido Pharma Inc. Announces Closing of $75 Million Bought Deal Offering of Common Stock

Released On: 2/19/2021
Views: 1044

https://s3.amazonaws.com/findit-pictures/351133/9642dc86-4305-4113-a789-78af0ea01972.jpg

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

AIkido Pharma Inc. Increases Previously Announced Bought Deal Offering of Common Stock to $75 Million

Released On: 2/16/2021
Views: 1138

https://s3.amazonaws.com/findit-pictures/351133/d64287af-b96d-47bb-a32b-65ddb76ff3d4.jpg

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

AIkido Pharma Inc. Announces $10 Million Bought Deal Offering Of Common Stock

Released On: 2/16/2021
Views: 1091

https://s3.amazonaws.com/findit-pictures/351133/54fa1d0c-edd2-4000-b922-08b0837dba1a.jpg

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

AIkido Pharma Enters Into Letter Of Intent With Silo Pharma for Use of Psilocybin and Peptide Therapy for Cancer Treatment

Released On: 2/16/2021
Views: 1229

https://s3.amazonaws.com/findit-pictures/351133/d6d4252d-f996-436f-bf91-6c83af43e756.jpg

Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine

Aikido Pharma Announces Information on KPC-34 Which Was Developed at the Wake Forest School of Medicine

Released On: 2/15/2021
Views: 887

https://s3.amazonaws.com/findit-pictures/351133/8ac95bfe-f94b-4b9f-b39a-98d7aa7f6abd.jpg

Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

Aikido Pharma Establishes Licensing Agreement with University of Maryland
for Antiviral Compounds, Including COVID-19

Released On: 2/10/2021
Views: 801

https://s3.amazonaws.com/findit-pictures/351133/cdbebd8e-c86d-4537-8940-1b1b2ea0b06e.jpg

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

Aikido Pharma Announces DHA-dFdC Which Is Licensed From the University of Texas at Austin for the treatment of Pancreatic Cancer.

Released On: 2/9/2021
Views: 1401

https://s3.amazonaws.com/findit-pictures/351133/09f4b098-397e-40d6-8af9-bacf930bb0cf.jpg

Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer

Aikido Pharma Secures Early Interest in Convergent Therapeutics, Inc. Who Focuses On Next Generation Radiopharmaceutical Therapy for Prostate Cancer

Released On: 2/5/2021
Views: 975

https://s3.amazonaws.com/findit-pictures/351133/59ca97a6-b0e3-47f3-adef-57939fddd0e5.jpg

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

AIkido Pharma Appoints Dr. Scott T. Tagawa, M.D. to Scientific Advisory Board

Released On: 2/3/2021
Views: 1852

https://s3.amazonaws.com/findit-pictures/351133/e6e1220e-0686-4d01-8029-a87b9d54e412.jpg

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

Meet Aikido Pharma A BioTechnology Development Company Focused on The Treatment Of Early and Mid-Stage Small-Molecule Anti-Cancer Therapeutics

Released On: 2/3/2021
Views: 1075

Load More wait

Map

Aikido Pharma

Get Directions

Aikido Pharma

  • One Rockefeller Plaza
    New York, New York 10020
    United States
  • (212) 745-1373